UOC
VKTX icon

UBS O'Connor’s Viking Therapeutics VKTX Stock Holding History

UBS O'Connor’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,000
Closed -$8.13K – 467
2024
Q4 		$8.13K Buy
25,000
+5,000
+25% +$285K ﹤0.01% 398
2024
Q3 		$68K Buy
20,000
+6,400
+47% +$375K ﹤0.01% 417
2024
Q2 		$102K Sell
13,600
-36,400
-73% -$2.39M ﹤0.01% 431
2024
Q1 		$388K Buy
+50,000
New +$2.22M 0.01% 353

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS O'Connor's VKTX Position: Q4 2024 in Review

UBS O'Connor sold out of Viking Therapeutics (VKTX) in Q4 2024, closing a stake of 11,316 shares — an estimated $645K sold.

UBS O'Connor first reported a position in VKTX in Q3 2018 and held it in 8 quarters. The position peaked at $1.66M in Q3 2018. 408 funds tracked by Wall St. Rank hold VKTX as of Q4 2024.

  • UBS O'Connor reported no remaining Viking Therapeutics position as of Q4 2024 after selling out during the quarter.
  • UBS O'Connor sold 11,316 Viking Therapeutics shares in Q4 2024, an estimated $645K.
  • UBS O'Connor first reported a position in Viking Therapeutics in Q3 2018 and held it in 8 quarters.
  • UBS O'Connor's Viking Therapeutics position peaked at $1.66M in Q3 2018.
  • 408 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2024.

Based on UBS O'Connor's 13F filing for Q4 2024, filed 14 Feb 2025.